BELLUS Health Inc. is a drug development company focused on rare diseases. The business activities of the Company are development of the Company's core technology platform, amyloid inhibitors, which focus on chemical compounds that could have the potential to inhibit the formation, deposition and toxicity of amyloid fibrils, which are the underlying causes of certain diseases. The Company operates in the business segment of development of drugs for health solutions. It is focused on developing drugs for rare diseases, starting with conditions that affect the kidneys. Its pipeline of rare disease projects includes KIACTA in Phase III for Amyloid A (AA) amyloidosis; KIACTA for sarcoidosis; clinical stage Shigamab for Hemolytic Uremic Syndrome caused by Shiga toxin-producing E. coli (sHUS), and a research-stage project for amyloid light-chain (AL) amyloidosis. It is partnered with global private equity firm Auven Therapeutics for the development of KIACTA.